{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:02:00Z","timestamp":1763726520706},"reference-count":17,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":3666,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Several large clinical trials suggest that ACE inhibitors may reduce the incidence of diabetes. Less is known about the effects of angiotensin receptor blockers (ARBs) on reducing incident diabetes or leading to regression of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) to normoglycemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. The participants were randomized to the ARB telmisartan 80 mg (n = 1,726) or placebo (n = 1,762) in addition to usual care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>During a median 56 months, 21.8% of participants treated with telmisartan and 22.4% of those on placebo developed diabetes (relative ratio 0.95 [95% CI 0.83\u20131.10]; P = 0.51). Participants originally diagnosed with IFG and\/or IGT were equally likely to regress to normoglycemia (26.9 vs. 24.5%) or to progress to incident diabetes (20.1 vs. 21.1%; P = 0.59) on telmisartan or placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>There was no evidence that addition of the ARB telmisartan to usual care prevents incident diabetes or leads to regression of IFG or IGT in people at high risk for cardiovascular disease but free from diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc11-0545","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T00:57:21Z","timestamp":1311641841000},"page":"1902-1907","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes"],"prefix":"10.2337","volume":"34","author":[{"given":"Joshua I.","family":"Barzilay","sequence":"first","affiliation":[{"name":"Kaiser Permanente of Georgia & Emory University School of Medicine, Atlanta, Georgia"}]},{"given":"Peggy","family":"Gao","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital, Stockholm, Sweden"}]},{"given":"Helmut","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany"}]},{"given":"Jeffrey","family":"Probstfield","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington School of Medicine, Seattle, Washington"}]},{"given":"Patrick","family":"Commerford","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town Observatory, Cape Town, South Africa"}]},{"given":"Antonio","family":"Dans","sequence":"additional","affiliation":[{"name":"Philippine General Hospital, Manila, Philippines"}]},{"given":"Rafael","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Praceta do Com\u00e9rcio, Amadora, Portugal"}]},{"given":"M\u00e1ty\u00e1s","family":"Keltai","sequence":"additional","affiliation":[{"name":"Semmelweis University, Gottsegen Gy\u00f6rgy Hungarian Institute of Cardiology, Budapest, Hungary"}]},{"given":"Ernesto","family":"Paolasso","sequence":"additional","affiliation":[{"name":"Estudios Cl\u00ednicos Latinoamerica, Rosario, Argentina"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}]},{"given":"Koon","family":"Teo","sequence":"additional","affiliation":[{"name":"Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}]},{"name":"on behalf of the TRANSCEND Investigators","sequence":"additional","affiliation":[]}],"member":"1167","published-online":{"date-parts":[[2011,8,19]]},"reference":[{"key":"2022031302403234200_B1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"2022031302403234200_B2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"2022031302403234200_B3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"Holman","year":"2010","journal-title":"N Engl J Med"},{"key":"2022031302403234200_B4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031302403234200_B5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ahj.2004.03.020","article-title":"Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET\/TRANSCEND) trials","volume":"148","author":"Teo","year":"2004","journal-title":"Am Heart J"},{"key":"2022031302403234200_B6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-4-6","article-title":"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome","volume":"4","author":"Vitale","year":"2005","journal-title":"Cardiovasc Diabetol"},{"key":"2022031302403234200_B7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.diabres.2008.07.003","article-title":"The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control","volume":"82","author":"Yamana","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031302403234200_B8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"2022031302403234200_B9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"The Claude Bernard Lecture 2009: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links.","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"2022031302403234200_B10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1559-4564.2007.06673.x","article-title":"The cardiometabolic syndrome and sarcopenic obesity in older persons","volume":"2","author":"Dominguez","year":"2007","journal-title":"J Cardiometab Syndr"},{"key":"2022031302403234200_B11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/ije\/dyp202","article-title":"Could mitochondrial efficiency explain the susceptibility to adiposity, metabolic syndrome, diabetes and cardiovascular diseases in South Asian populations?","volume":"38","author":"Bhopal","year":"2009","journal-title":"Int J Epidemiol"},{"key":"2022031302403234200_B12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.hjh.0000160198.05416.72","article-title":"Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes","volume":"23","author":"Jandeleit-Dahm","year":"2005","journal-title":"J Hypertens"},{"key":"2022031302403234200_B13","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"key":"2022031302403234200_B14","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","article-title":"The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"key":"2022031302403234200_B15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1751-7176.2010.00335.x","article-title":"Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension","volume":"12","author":"Hsueh","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2022031302403234200_B16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc06-1745","article-title":"Effects of angiotensin II type 1 receptor blockade on \u03b2-cell function in humans","volume":"30","author":"Bokhari","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302403234200_B17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1055\/s-0029-1240928","article-title":"A European evidence-based guideline for the prevention of type 2 diabetes","volume":"42","author":"Paulweber","year":"2010","journal-title":"Horm Metab Res"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/9\/1902\/609530\/1902.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/9\/1902\/609530\/1902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T01:57:29Z","timestamp":1647136649000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/34\/9\/1902\/38628\/Effects-of-Telmisartan-on-Glucose-Levels-in-People"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,19]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,8,19]]},"published-print":{"date-parts":[[2011,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc11-0545","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"type":"print","value":"0149-5992"},{"type":"electronic","value":"1935-5548"}],"subject":[],"published":{"date-parts":[[2011,8,19]]}}}